Experimental virus vaccine takes on multiple cancers in early trial
NCT ID NCT05492682
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 31 times
Summary
This early-phase trial is testing a new virus-based cancer vaccine (PeptiCRAd-1) combined with the immunotherapy drug pembrolizumab in 15 people with various solid tumors like melanoma, triple-negative breast cancer, and lung cancer. The main goal is to see if the combination is safe and whether it sparks an immune response against cancer. All participants receive the vaccine, a single dose of cyclophosphamide, and six doses of pembrolizumab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Istituto Clinico Humanitas
NOT_YET_RECRUITINGMilan, Italy
Contact Email: •••••@•••••
-
IRCCS Ospedale San Raffaele
NOT_YET_RECRUITINGMilan, Italy
Contact Email: •••••@•••••
-
Istituto di Candiolo Fondazione del Piemonte per l'oncologia IRCCS
RECRUITINGCandiolo, Italy
Contact Email: •••••@•••••
-
Krankenhaus Nordwest
ACTIVE_NOT_RECRUITINGFrankfurt, Germany
-
National Center for Tumor Diseases
COMPLETEDHeidelberg, Germany
-
Università di Napoli Federico II
NOT_YET_RECRUITINGNaples, Italy
Contact Email: •••••@•••••
-
Universitätsklinikum Tübingen
COMPLETEDTübingen, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PeptiCRAd-1 (a virus-based cancer vaccine) combined with pembrolizumab (an immunotherapy drug)
What this could lead to
If this early trial shows the combination is safe and boosts the immune system against tumors, it could point toward a new treatment option for several hard-to-treat cancers.
What could go wrong
This is a very small, early-phase (Phase 1) study with only 15 people. The main goal is safety, not effectiveness. The treatment may not shrink tumors or could cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.